Table 3.
Clinical trials including bladder cancer with agents targeting macrophages.
| Targeted Pathways | Agent Names | Combinations | Tumor Types | Clinical Phases | Trial Numbers |
|---|---|---|---|---|---|
| TLR | BDB001 | Atezolizumab + Radiotherapy | Advanced solid tumors * | II | NCT03915678 |
| Imiquimod | Carcinoma in situ bladder cancer | II | NCT01731652 | ||
| Imiquimod | TRK-950 | Advanced solid tumors * | I | NCT03872947 | |
| Poly(I:C) | PGV001 + Atezolizumab | Urothelial/bladder cancer | I | NCT03359239 | |
| Poly(I:C) | Durvalumab +/− Tremelimumab | Advanced solid tumors * | I/II | NCT02643303 | |
| HDAC | Abexinostat | Pembrolizumab | Advanced solid tumor * | I | NCT03590054 |
| Belinostat | Bladder cancer | I/II | NCT00421889 | ||
| Chidamide | Tislelizumab | Bladder cancer stage IV | II | NCT04562311 | |
| Domatinostat | Nivolumab +/− Ipilimumab | Urothelial carcinoma | I | NCT04871594 | |
| Entinostat | Pembrolizumab | MIBC | II | NCT03978624 | |
| FR901228 | Advanced urothelial carcinoma | II | NCT00087295 | ||
| Mocetinostat | Urothelial carcinoma | II | NCT02236195 | ||
| Romidepsin | Solid tumors * | I | NCT01638533 | ||
| Vorinostat | Locally recurrent or metastatic urothelial carcinoma | II | NCT00363883 | ||
| Vorinostat | Docetaxel | Advanced and relapsed solid tumors * | I | NCT00565227 | |
| Vorinostat | Pembrolizumab | Advanced urothelial cell carcinoma | I | NCT02619253 | |
| PI3K | Buparlisib | Metastatic urothelial carcinoma | II | NCT01551030 | |
| Copanlisib Copanlisib Hydrochloride GSK2636771 Taselisib |
Advanced solid tumors * | II | NCT02465060 | ||
| Eganelisib | Nivolumab | Advanced urothelial carcinoma | II | NCT03980041 | |
| CD40 | APX005M | Urothelial carcinoma | I | NCT02482168 | |
| CDX-1140 | +/− CDX-301 +/− Pembrolizumab +/− Chemotherapy | Advanced solid tumors * | I | NCT03329950 | |
| CD47 | Hu5F9-G4 | Atezolizumab | Cisplatin-ineligible MIBC and locally advanced or metastatic urothelial carcinoma | I/II | NCT03869190 |
*: in tumor types, the study specified that bladder cancer or urothelial carcinoma are included. HDAC: histone deacetylase; PI3 K: phosphoinositide 3-kinase; TLR: Toll-like receptor.